In the first ever meeting of Indian and Chinese drug regulators, Indian representatives pressed their counterparts for a clear roadmap to open up the Chinese pharmaceuticals market for Indian exports, The Economic Times.
The crucial meeting took place on Friday (21 June) at Shanghai. The meeting gains significance as Indian officials have for long been pressing over China to allow Indian companies wider access to the Chinese pharmaceuticals market which is presently under pressure because of high prices of cancer and generic drugs.
The meeting went on for as much as nine hours and included senior officials from the Ministry of Commerce and also diplomats to aid the discussion. The Indian Ambassador to China, Vikram Misri, also emphasised the need to hold such meetings in a regular fashion.
The meeting deliberated upon different subjects in six sessions, such as regulatory overview of the National Medical Products Administration (NMPA), registration of imported drugs in China, Indian regulatory system, drug procurement system in China, NMPA overseas inspections and compliance guide, API (Active Pharmaceutical Ingredient) registration process in China.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.